These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 22045523)

  • 1. [Proteins in haematology].
    Clarenbach RE; Mey U
    Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-based therapy of non-Hodgkin's lymphoma.
    Foran JM
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal antibodies in hematology in 2009].
    Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
    Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody therapy of lymphoma.
    Illidge TM; Bayne MC
    Expert Opin Pharmacother; 2001 Jun; 2(6):953-61. PubMed ID: 11585011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monoclonal antibody treatment of malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy in lymphoid malignancies.
    Hainsworth JD
    Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ten years since the successful introduction of the first monoclonal antibody (rituximab) into the therapy of lymphomas].
    Trnený M; Klener P
    Cas Lek Cesk; 2007; 146(7):578-85. PubMed ID: 17722844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody therapy for chronic lymphocytic leukemia.
    Christian BA; Lin TS
    Semin Hematol; 2008 Apr; 45(2):95-103. PubMed ID: 18381104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.